On October 4th, ASBM Executive Director Michael Reilly met with several Canadian health officials in Ottawa to discuss naming and substitution policy, and preview data from ASBM’s Canadian prescriber survey which will be released October 17th at the DIA Canada Annual Meeting in Ottawa.
While in Ottawa, Mr. Reilly met with the Minister of Health’s Office, the Minister of Innovation, Science, and Economic Development’s Office, the Prime Minister’s Office, the Chair of the Parliamentary Standing Committee on Health, Health Canada’s Office of Policy and International Collaboration, and its Biologics and Genetic Therapies Directorate.
